Taro Pharmaceutical Industries Ltd. (TARO): Price and Financial Metrics

TARO POWR Grades

• TARO scores best on the Value dimension, with a Value rank ahead of 96.39% of US stocks.
• The strongest trend for TARO is in Growth, which has been heading down over the past 177 days.
• TARO's current lowest rank is in the Growth metric (where it is better than 9.42% of US stocks).

TARO Stock Summary

• The ratio of debt to operating expenses for TARO PHARMACEUTICAL INDUSTRIES LTD is higher than it is for about just 0.44% of US stocks.
• Equity multiplier, or assets relative to shareholders' equity, comes in at 1.25 for TARO PHARMACEUTICAL INDUSTRIES LTD; that's greater than it is for just 15.55% of US stocks.
• In terms of twelve month growth in earnings before interest and taxes, TARO PHARMACEUTICAL INDUSTRIES LTD is reporting a growth rate of -1,171.59%; that's higher than merely 1.63% of US stocks.
• If you're looking for stocks that are quantitatively similar to TARO PHARMACEUTICAL INDUSTRIES LTD, a group of peers worth examining would be UPC, RLX, FALC, GENC, and AVGR.
• Visit TARO's SEC page to see the company's official filings. To visit the company's web site, go to www.taro.com.

TARO Valuation Summary

• In comparison to the median Healthcare stock, TARO's price/sales ratio is 65.96% lower, now standing at 1.6.
• TARO's EV/EBIT ratio has moved up 8.1 over the prior 243 months.

Below are key valuation metrics over time for TARO.

TARO Growth Metrics

Its year over year net income to common stockholders growth rate is now at 115.07%.
• Its 2 year net income to common stockholders growth rate is now at -76.14%.
• Its 2 year net cashflow from operations growth rate is now at -158.43%.

TARO's revenue has moved down $80,339,000 over the prior 33 months.

The table below shows TARO's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-09-30	569.411	-188.342	64.983
2022-06-30	570.899	-260.719	91.113
2022-03-31	561.347	-158.698	58.266
2022-03-31	561.347	-158.698	58.267
2021-12-31	566.431	-148.901	1.077
2021-09-30	567.592	85.894	7.683

TARO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• TARO has a Quality Grade of B, ranking ahead of 81% of graded US stocks.
• TARO's asset turnover comes in at 0.239 -- ranking 182nd of 682 Pharmaceutical Products stocks.
• ELTP, ADMP, and ENTA are the stocks whose asset turnover ratios are most correlated with TARO.

The table below shows TARO's key quality metrics over time.